Frost & Sullivan is media partner for this event which will be looking at Open & Collaborative Innovation specifically in life sciences industry.

"Open-innovation" is a concept that has been discussed a lot in recent times across many knowledge-intensive high-tech industries, including one as innovation-dependent as the global life sciences industry. The idea of pooling risk, costs and resources, whilst hopefully increasing R&D productivity at the same time through collaborative innovation is attractive in theory, although difficult in practice in an industry when IP protection is paramount. The Human Genome Project, for example, is the greatest successful example of life science innovation and through "open" collaborative channels. Drug developers for example, are facing an acute R&D productivity crisis, with ever-decreasing numbers of molecules ever reaching the market, whilst R&D spending has been increasing rapidly at the same time. Both regulators and payers are increasingly risk-averse, and "innovation" is being redefined in terms of what the customer needs and what they're prepared to pay for.

• Understand what is meant by "open-innovation" in practice and how this can work in life sciences.
• Hear real-life examples of successful implementation from pharmaceutical companies, academic-led consortia, non-profits and public-private partnerships.
• Appreciate if the benefits outweigh the costs, as well as answers to the questions what? With who? When? Why? How? And how much?
• Determine how best to share information, risks and costs with R&D partners, whilst protecting intellectual property and maximising the benefits of joint synergies.
• Find out what are the do's and don'ts in opening-up R&D to outsiders.
• Discover if "open-innovation" can truly improve R&D productivity, compared to the current model and strong tradition of R&D collaborations and alliances.

• Life science industry: VPs, Directors of discovery, R&D, innovation, chief scientific officers, therapy area heads, pre-clinical research, licensing, business development, alliances and collaborations, knowledge management, R&D Outsourcing.
• Academia, technology transfer, government and non-profit research institutes.

To request the full agenda please follow the link:

http://www.nextlevelpharma.com/events/request_agenda/
open_collaborative_innovation_in_life_science_r_d

Erika Vavrovicova
Tel: +421 232 660 382
Fax: +421 232 660 397
Email: erika@nextlevelpharma.com
Visit: www.nextlevelpharma.com